Literature DB >> 18685379

How does cachexia influence survival in cancer, heart failure and other chronic diseases?

Mitja Lainscak1, Matej Podbregar, Stefan D Anker.   

Abstract

PURPOSE OF REVIEW: Metabolic, immunological and neurohormonal disturbances, body wasting, and poor patient performance frequently accompany chronic disease. Ultimately, cachexia may develop in 10-15% of patients, who usually perish soon after. We currently have neither a globally accepted definition of cachexia nor any treatment to prevent or treat cachexia. RECENT
FINDINGS: Cachexia remains an unresolved issue in modern medicine. Despite its significant prevalence and poor prognosis, debate on the global definition of cachexia continues. We require a clinical definition, which should include the significant weight loss and its dynamics. There is accumulating evidence that various chronic diseases share pathophysiological mechanisms that lead to wasting and ultimately cachexia. Reversal of traditional cardiovascular risk factors is of value not only in chronic heart failure but also in chronic kidney disease and chronic obstructive pulmonary disease.
SUMMARY: Future trials to improve prognosis in patients with cachexia will require a global definition of cachexia and identification of key underlying mechanisms. Results with neurohormonal antagonists are intriguing, and clinical use of these agents would be feasible. While searching for treatments for full-blown cachexia, we should also aim to identify treatments directed at the causes in order to prevent its development.

Entities:  

Mesh:

Year:  2007        PMID: 18685379     DOI: 10.1097/SPC.0b013e3282f31667

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  11 in total

1.  TRIF is a key inflammatory mediator of acute sickness behavior and cancer cachexia.

Authors:  Kevin G Burfeind; Xinxia Zhu; Peter R Levasseur; Katherine A Michaelis; Mason A Norgard; Daniel L Marks
Journal:  Brain Behav Immun       Date:  2018-05-28       Impact factor: 7.217

2.  Elevated TNFalpha production in whole blood in patients with severe COPD: the potential link to disease severity.

Authors:  Stephan von Haehling; Nicholas S Hopkinson; Michael I Polkey; Margit Niethammer; Stefan D Anker; Sabine Genth-Zotz
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer.

Authors:  Mihael Sok; Janez Ravnik; Maja Ravnik
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  Dynapenia and aging: an update.

Authors:  Todd M Manini; Brian C Clark
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-03-28       Impact factor: 6.053

5.  Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585.

Authors:  Julia Schreml; Markus Riessland; Mario Paterno; Lutz Garbes; Kristina Roßbach; Bastian Ackermann; Jan Krämer; Eilidh Somers; Simon H Parson; Raoul Heller; Albrecht Berkessel; Anja Sterner-Kock; Brunhilde Wirth
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

6.  The link of unintentional weight loss to cardiac event-free survival in patients with heart failure.

Authors:  Eun Kyeung Song; Yongjik Lee; Debra K Moser; Rebecca L Dekker; Seok-Min Kang; Terry A Lennie
Journal:  J Cardiovasc Nurs       Date:  2014 Sep-Oct       Impact factor: 2.083

7.  Analysis of skeletal muscle gene expression patterns and the impact of functional capacity in patients with systolic heart failure.

Authors:  Daniel E Forman; Karla M Daniels; Lawrence P Cahalin; Alexandra Zavin; Kelly Allsup; Peirang Cao; Mahalakshmi Santhanam; Jacob Joseph; Ross Arena; Antonio Lazzari; P Christian Schulze; Stewart H Lecker
Journal:  J Card Fail       Date:  2014-04-02       Impact factor: 5.712

8.  Why do thin people have elevated all-cause mortality? Evidence on confounding and reverse causality in the association of adiposity and COPD from the British Women's Heart and Health Study.

Authors:  Caroline Dale; Eveline Nüesch; David Prieto-Merino; Minkyoung Choi; Antoinette Amuzu; Shah Ebrahim; Juan P Casas; George Davey-Smith
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

9.  One-year prevalence, comorbidities and cost of cachexia-related inpatient admissions in the USA.

Authors:  Susan Tsivitse Arthur; Joshua M Noone; Bryce A Van Doren; Debosoree Roy; Christopher M Blanchette
Journal:  Drugs Context       Date:  2014-07-31

10.  Micro-computed tomography for non-invasive evaluation of muscle atrophy in mouse models of disease.

Authors:  Laura Pasetto; Davide Olivari; Giovanni Nardo; Maria Chiara Trolese; Caterina Bendotti; Rosanna Piccirillo; Valentina Bonetto
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.